MGB Biopharma Ltd.
This article was originally published in Start Up
MGB Biopharma Ltd. believes it may be able to create compounds that directly kill bacteria before they ever have a chance to mutate. Its plan is to develop chemicals that bind to bacterial DNA and stop transcription of key genes. Indeed, the fi rst three letters of the company’s name stand for minor groove binders, because this is the class of drug that management aspires to develop as antibacterials.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. "As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors," features profiles of Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharmaceuticals. Plus these Start-Ups Across Health Care: CardioPhotonics, Eureka Genomics, Invuity and OrthoSensor.
Kenta Biotech Ltd., is betting that fully human monoclonal antibodies will become valuable treatments for hospitalized patients battling serious bacterial infections. Some strong clinical data is giving Kenta confidence. It recently reported positive results from a Phase IIa clinical trial of critically ill patients with hospital-acquired and ventilator-acquired pneumonia caused by pseudomonas aeruginosa. All those who completed the three-infusion course of Kenta’s lead candidate survived and fully cleared their pneumonia. No negative systemic or infusion-site responses were reported.
VCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.